Clinical Trial Update: A Long Term Safety and Efficacy Study of Fabrazyme Replacement Therapy in Japanese Patients With Fabry Disease.

View source ↗

Summary

This clinical trial update describes the long-term safety and efficacy study of Fabrazyme (agalsidase beta) in Japanese patients with Fabry disease. The study, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• FABRAZYME (Agalsidase beta)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Fabry Disease | Status: COMPLETED